ART Bioscience Company
ART is a company based on novel messenger RNA (mRNA) technologies for the development of new therapeutics that can potentially change the course of the Duchenne disease. ART BioScience is committed to the development of a new class of therapeutics based on messenger RNA (mRNA) for the treatment of Orphan diseases, primarily Duchenne Muscular Dystrophy.
Technology:
Biotechnology, Medical
Industry:
Personalized Medicine
Headquarters:
Rehovot, Israel
Founded Date:
2015
Employees Number:
Undisclosed
Funding Status:
N/A
Register and Claim Ownership